Prophylactic milrinone during OPCAB of posterior vessels: implication in angina patients taking beta-blockers.
OBJECTIVE
To determine whether a phosphodiesterase type 3 inhibitor can improve hemodynamics during off-pump coronary artery bypass grafting (OPCAB) of posterior vessels in patients on beta(1)-adrenoreceptor blockers.


METHODS
Thirty patients scheduled for OPCAB of the obtuse marginal artery (OM), and taking atenolol 100 mg a day were randomized in a double-blind manner to receive either milrinone or placebo. Hemodynamic data were obtained after induction, before pericardial incision, during left anterior descending artery grafting, during OM grafting, and after removal of the stabilizer. During the OM grafting, dopamine was infused when the cardiac index (CI) decreased below 2.0 L/min/m(2), and phenylephrine was infused to maintain the arterial pressure with a CI above 2.0 L/min/m(2).


RESULTS
During OM anastomosis, there were significant differences in CI (milrinone [M] = +7.7%, control [C] = -13.7%, p=0.01), SVI (M=-21.5%, C=-35.8%, p=0.03), SvO(2) (M=-2.6%, C=-8.9%, p=0.02), and SVR (M=-28.1%, C=+1.1%, p=0.01) between the two groups, in terms of percentage change from baseline value. Dopamine was required more frequently and at a higher dose in the control group (M=13%, 5.0 microg/kg/min; C=67%, 10.1 microg/kg/min, p<0.05). Phenylephrine was infused in 33% of the patients in the milrinone group compared to 13% in the control group (p>0.05).


CONCLUSIONS
Prophylactic milrinone improves CI, SVI and SvO(2) reducing the need for high doses of dopamine during OM anastomosis in patients taking atenolol. Therefore, it can be used as an alternative to dopamine improving hemodynamics and organ perfusion during OPCAB of posterior vessels in patients on beta(1)-blockers.
Department of Anesthesiology, Seoul City Boramae Hospital, Shindaebang-Dong, Dongjak-gu, Seoul 156-707, South Korea.
Jin-Hee
JH
Kim
Byung Moon
BM
Ham
Yong Lak
YL
Kim
Jae-Hyon
JH
Bahk
Ho-Geol
HG
Ryu
Yoon-Seok
YS
Jeon
Ki-Bong
KB
Kim
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000379:methods*; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D004311:Double-Blind Method; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007430:Intraoperative Care / Q000379:methods; D007431:Intraoperative Complications / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D020105:Milrinone / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000517:prevention & control; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents; D010726:Phosphodiesterase Inhibitors; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D020105:Milrinone